On June 8, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 14th International Conference on Malignant Lymphoma (ICML), to be held from June 14 – 17, 2017, in Lugano, Switzerland (Press release, TG Therapeutics, JUN 8, 2017, View Source [SID1234519476]). The abstracts were made public yesterday, and are included in the Abstract Book available through the ICML meeting website at www.lymphcon.ch. Schedule your 30 min Free 1stOncology Demo! Details of the data presentations are outlined below.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentations:
Title: Updated results of a multicenter phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL
Abstract Number: 040
Presentation Date & Time: Wednesday, June 14, 2017 17:50 CEST
Session Title: Chemotherapy-Free Combinations
Presenter: Matthew S. Davids, MD, Dana-Farber Cancer Institute
Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
Abstract Number: 101
Presentation Date & Time: Friday, June 16, 2017 11:20 CEST
Session Title: Session 7 – Advances in CLL
Presenter: Anthony R. Mato, MD, University of Pennsylvania, Abramson Cancer Center
Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
Abstract Number: 102
Presentation Date & Time: Friday, June 16, 2017 11:35 CEST
Session Title: Session 7 – Advances in CLL
Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center
Poster Presentation:
Title: Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma
Abstract Number: 277
Presentation Date: Friday, June 16, 2017 (Poster Session)
Presenter: Mathew Lunning, DO, University of Nebraska, Omaha, NE
Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
On May 19, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 14th International Conference on Malignant Lymphoma (ICML), to be held from June 14 – 17, 2017, in Lugano, Switzerland (Press release, TG Therapeutics, MAY 19, 2017, View Source [SID1234519241]). Schedule your 30 min Free 1stOncology Demo! Details of the data presentations are outlined below.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentations:
Title: Updated results of a multicenter phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL
Abstract Number: 040
Presentation Date & Time: Wednesday, June 14, 2017 17:50 CEST
Session Title: Chemotherapy-Free Combinations
Presenter: Matthew S. Davids, MD, Dana-Farber Cancer Institute
Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
Abstract Number: 101
Presentation Date & Time: Friday, June 16, 2017 11:20 CEST
Session Title: Session 7 – Advances in CLL
Presenter: Anthony R. Mato, MD, University of Pennsylvania, Abramson Cancer Center
Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
Abstract Number: 102
Presentation Date & Time: Friday, June 16, 2017 11:35 CEST
Session Title: Session 7 – Advances in CLL
Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center
In addition to the above oral presentations, a poster titled "Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma" has been accepted for poster presentation during the conference. Additional details on this presentation will be available in June.
The above abstracts will be included in the Abstract Book available online on Wednesday, June 7, 2017 through the ICML meeting website at www.lymphcon.ch. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.